⌘K
Loading ticker…
As of 2026-08-24, Citius Pharmaceuticals Inc. Common (CTXR) has a 3-month relative strength percentile of 22 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 12.0%, relative volume 0.39×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CTXR is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -1.8% / -26.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CTXR appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $151K notional.
Held by 1 ETFs · $151K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $151K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CTXR Jan avg: 5.13% median: -11.33% win: 25% σ: 48.58% n: 4 2022-04-12 → 2026-07-31 | CTXR Feb avg: -8.05% median: -8.64% win: 25% σ: 26.43% n: 4 2022-04-12 → 2026-07-31 | CTXR Mar avg: 7.61% median: 9.26% win: 75% σ: 14.31% n: 4 2022-04-12 → 2026-07-31 | CTXR Apr avg: -19.81% median: -22.67% win: 20% σ: 27.33% n: 5 2022-04-12 → 2026-07-31 | CTXR May avg: -10.10% median: -6.96% win: 0% σ: 5.90% n: 5 2022-04-12 → 2026-07-31 | CTXR Jun avg: 22.23% median: -2.10% win: 40% σ: 62.81% n: 5 2022-04-12 → 2026-07-31 | CTXR Jul avg: 3.01% median: -5.71% win: 20% σ: 29.68% n: 5 2022-04-12 → 2026-07-31 | CTXR Aug avg: -2.51% median: -5.38% win: 25% σ: 30.76% n: 4 2022-04-12 → 2026-07-31 (current) | CTXR Sep avg: -11.39% median: -9.47% win: 0% σ: 10.03% n: 4 2022-04-12 → 2026-07-31 | CTXR Oct avg: 0.27% median: -0.39% win: 50% σ: 23.23% n: 4 2022-04-12 → 2026-07-31 | CTXR Nov avg: -15.62% median: -3.21% win: 50% σ: 33.27% n: 4 2022-04-12 → 2026-07-31 | CTXR Dec avg: -14.98% median: -17.17% win: 25% σ: 30.00% n: 4 2022-04-12 → 2026-07-31 |